CORBUS PHARMACEUTICALS
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum i... s currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.
CORBUS PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Pharmaceutical
Founded:
2009-01-01
Address:
Norwood, Massachusetts, United States
Country:
United States
Website Url:
http://www.corbuspharma.com
Total Employee:
51+
Status:
Active
Contact:
(617) 963-0100
Email Addresses:
[email protected]
Total Funding:
196.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Domain Not Resolving
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Founder
Stock Details
Investors List
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Corbus Pharmaceuticals
Ghost Tree Capital Group
Ghost Tree Capital Group investment in Post-IPO Equity - Corbus Pharmaceuticals
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Corbus Pharmaceuticals
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Corbus Pharmaceuticals
Fort Point Angels
Fort Point Angels investment in Venture Round - Corbus Pharmaceuticals
Oleg Uritsky
Oleg Uritsky investment in Venture Round - Corbus Pharmaceuticals
SternAegis
SternAegis investment in Venture Round - Corbus Pharmaceuticals
Boston Harbor Angels
Boston Harbor Angels investment in Angel Round - Corbus Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-07 | Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer |
Official Site Inspections
http://www.corbuspharma.com Semrush global rank: 9.44 M Semrush visits lastest month: 157
- Host name: ec2-34-226-46-235.compute-1.amazonaws.com
- IP address: 34.226.46.235
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Corbus Pharmaceuticals"
Overview : Corbus Pharmaceuticals Holdings, Inc.
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013.See details»
Corbus Pharmaceuticals - LinkedIn
Corbus Pharmaceuticals | 16,274 followers on LinkedIn. Committed to leveraging expertise in immunology to fulfill purpose of developing innovative new medicines | Corbus is a precision โฆSee details»
Corbus Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (617) 963-0100 Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the โฆSee details»
Corbus Pharmaceuticals - Craft
Oct 29, 2024 Corbus Pharmaceuticals has 5 employees at their 1 location and $881.71 k in annual revenue in FY 2021. See insights on Corbus Pharmaceuticals including office โฆSee details»
Corbus Pharmaceuticals Company Profile | Management and
SQL International Organization for Standardization . Python Python Software Foundation . Other Communication and Collaboration Software (3 Technologies) ... [email protected]: โฆSee details»
Leadership Team & Board of Directors
Ms. Jacques is the former President and Chief Executive Officer of Akari Therapeutics, Plc (Nasdaq: AKTX) (โAkariโ), a late-stage biopharmaceutical company focused on innovative โฆSee details»
Corbus Pharmaceuticals Holdings Inc, 3371:STU profile - FT.com
May 12, 2025 Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness โฆSee details»
Working at Corbus Pharmaceuticals - Zippia
Mar 14, 2024 www.corbuspharma.com. Organization Type. Public. CEO. Yuval Cohen. Social Media. Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical โฆSee details»
Profile : Corbus Pharmaceuticals Holdings, Inc.
Address: 500 River Ridge Drive Norwood, MA 02062 US. Telephone: 617.963.0100. Fax: 617.663.6085. Email: [email protected]See details»
Corbus Pharmaceuticals Company Overview, Contact Details
Jan 31, 2024 [email protected]: 22%. [email protected]: [email protected]: 2%. [email protected]: [email protected]: 1%. โฆSee details»
Corbus Pharma - 2025 Company Profile - Tracxn
6 days ago Corbus Pharma has raised a total funding of $10.4M over 5 rounds. Its first funding round was on Sep 17, 2012. Its latest funding round was a Grant (prize money) round on Jan โฆSee details»
Our Company : Corbus Pharmaceuticals Holdings, Inc.
Our Company We are focused on connecting innovation to purpose. Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative โฆSee details»
Corbus Pharmaceuticals Names Industry Veteran Rachelle
9 hours ago NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on โฆSee details»
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End โฆ
Mar 12, 2024 [email protected]. Bruce Mackle Managing Director LifeSci Advisors, LLC [email protected] to follow---Corbus Pharmaceuticals โฆSee details»
About Corbus Pharmaceuticals Holdings
Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the โฆSee details»
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results โฆ
Mar 11, 2025 Financial Results for the Quarter and Year Ended December 31, 2024: The Company reported a net loss of approximately $9.5 million, or a net loss per diluted share of โฆSee details»
Working Here : Corbus Pharmaceuticals Holdings, Inc.
Own compassion. Who are we looking for? Barrier breakers.You have grit and resilience because good medicine and strong science is worth fighting for. What we can offer?See details»
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques โฆ
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today โฆSee details»
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial โฆ
Nov 12, 2021 Corbus' current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of โฆSee details»
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial โฆ
Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFฮฒ and small molecules that activate or inhibit the endocannabinoid system. Corbus is โฆSee details»